title: Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers.
abstract: BACKGROUND
  It has been suggested that phosphodiesterase 5 (PDE5) inhibition is potentially hazardous and that it increases the risk of cardiac events in patients with coronary artery disease. This study sought to evaluate whether PDE5 inhibition with sildenafil exerts any effect on exercise-induced myocardial ischemia in patients on beta-blockers.
  
  
  METHODS
  Fourteen patients underwent a baseline exercise test off-therapy and were then started on atenolol (100 mg once daily). After a run-in phase of 1 week, patients underwent a second exercise test and were randomized to receive either sildenafil (50 mg) or placebo given in a random order on two different occasions, 2 days apart. Exercise test was repeated 2 hours after the administration of sildenafil or placebo.
  
  
  RESULTS
  All patients had a > 1 mm ST-segment depression while off-therapy. Eight patients had a negative exercise test response after atenolol, which was unaltered by the adjunct of either sildenafil or placebo. In the remaining subjects, atenolol significantly prolonged the time to 1 mm ST-segment depression and the exercise time. Sildenafil and placebo did not reverse the beneficial effect of atenolol upon exercise-induced myocardial ischemia.
  
  
  CONCLUSIONS
  PDE5 inhibition does not worsen exercise capacity and exercise-induced myocardial ischemia in patients with chronic stable angina whose symptoms and exercise test response are well controlled by beta-blocker therapy.
authors.affiliation: Department of Internal Medicine, San Raffaele Rome, Tosinvest Sanità, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Patrizi
authors.forename: F
authors.initials: F
authors.lastname: Leonardo
authors.forename: F
authors.initials: F
authors.lastname: Pelliccia
authors.forename: S L
authors.initials: SL
authors.lastname: Chierchia
authors.forename: P
authors.initials: P
authors.lastname: Galetta
authors.forename: E
authors.initials: E
authors.lastname: Cerquetani
authors.forename: F
authors.initials: F
authors.lastname: Frascà
authors.forename: M
authors.initials: M
authors.lastname: Fini
authors.forename: G M
authors.initials: GM
authors.lastname: Rosano
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000150:complications / Q000188:drug therapy*; D001262:Atenolol / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002908:Chronic Disease; D000075202:Contraindications; D004347:Drug Interactions; D005080:Exercise Test; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000209:etiology / Q000503:physiopathology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
chemical_list: D000319:Adrenergic beta-Antagonists; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D001262:Atenolol; D000068677:Sildenafil Citrate